Research graph
References from Advanced lipid nanoparticles for targeted nucleic acid delivery. Local targets link to admitted publications; unresolved targets remain external evidence.
The current landscape of nucleic acid therapeutics
10.1038/s41565-021-00898-0 · 2021 · External reference
Nucleic acid therapeutics: Past, present, and future
10.1016/j.omtn.2024.102440 · 2025 · External reference
Nucleic acid delivery for therapeutic applications
10.1016/j.addr.2021.113834 · 2021 · External reference
Nucleic acid-based drugs for patients with solid tumours
10.1038/s41571-024-00883-1 · 2024 · External reference
Nucleic acid-based technologies targeting coronaviruses
10.1016/j.tibs.2020.11.010 · 2021 · External reference
Single-dose gene-replacement therapy for spinal muscular atrophy
10.1056/nejmoa1706198 · 2017 · External reference
Precision immunomodulation with synthetic nucleic acid technologies
10.1038/s41578-019-0105-4 · 2019 · External reference
Gene therapy for visual loss: Opportunities and concerns
10.1016/j.preteyeres.2018.08.003 · 2019 · External reference
The clinical progress of mRNA vaccines and immunotherapies
10.1038/s41587-022-01294-2 · 2022 · External reference
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
10.1038/s41565-019-0591-y · 2019 · External reference
Overcoming pharmaceutical bottlenecks for nucleic acid drug development
10.1021/acs.accounts.2c00464 · 2023 · External reference
Nontoxic nanopore electroporation for effective intracellular delivery of biological macromolecules
10.1073/pnas.1818553116 · 2019 · External reference
High-throughput nuclear delivery and rapid expression of DNA via mechanical and electrical cell-membrane disruption
10.1038/s41551-017-0039 · 2017 · External reference
Efficient generation of targeted large insertions by microinjection into two-cell-stage mouse embryos
10.1038/nbt.4166 · 2018 · External reference
Engineering adeno-associated virus vectors for gene therapy
10.1038/s41576-019-0205-4 · 2020 · External reference
Viral vector platforms within the gene therapy landscape
10.1038/s41392-021-00487-6 · 2021 · External reference
Immune responses to viral gene therapy vectors
10.1016/j.ymthe.2020.01.001 · 2020 · External reference
Lipid nanoparticles for mRNA delivery
10.1038/s41578-021-00358-0 · 2021 · External reference
Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape
10.1038/nbt.2612 · 2013 · External reference
Lipid nanoparticle topology regulates endosomal escape and delivery of RNA to the cytoplasm
10.1073/pnas.2301067120 · 2023 · External reference
Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
10.1056/nejmoa2034577 · 2020 · External reference
Lipid nanoparticles enabling gene therapies: From concepts to clinical utility
10.1089/nat.2018.0721 · 2018 · External reference
Interactions of apolipoproteins with lipid-based nanoparticles
10.1021/acsnano.2c10790 · 2023 · External reference
Chemical and structural modifications of RNAi therapeutics
10.1016/j.addr.2015.10.015 · 2016 · External reference
Recent progress in non-native nucleic acid modifications
10.1039/d0cs01430c · 2021 · External reference
Opportunities and challenges for antisense oligonucleotide therapies
10.1002/jimd.12251 · 2021 · External reference
Antisense oligonucleotides: The next frontier for treatment of neurological disorders
10.1038/nrneurol.2017.148 · 2018 · External reference
Nusinersen: A novel antisense oligonucleotide for the treatment of spinal muscular atrophy
10.5863/1551-6776-24.3.194 · 2019 · External reference
Chemical modification and design of anti-miRNA oligonucleotides
10.1038/gt.2011.100 · 2011 · External reference
Chemical strategies to modulate and manipulate RNA epigenetic modifications
10.1021/acs.accounts.4c00844 · 2025 · External reference
N1-methylpseudouridine and pseudouridine modifications modulate mRNA decoding during translation
10.1038/s41467-024-51301-0 · 2024 · External reference
Chemical modifications of mRNA ends for therapeutic applications
10.1021/acs.accounts.3c00442 · 2023 · External reference
GalNAc-siRNA conjugates: Leading the way for delivery of RNAi therapeutics
10.1089/nat.2018.0736 · 2018 · External reference
Poly (ethylene glycol) in drug delivery: Pros and cons as well as potential alternatives
10.1002/anie.200902672 · 2010 · External reference
Acid-degradable lipid nanoparticles enhance the delivery of mRNA
10.1038/s41565-024-01765-4 · 2024 · External reference
Recent advances in lipid nanoparticles and their safety concerns for mRNA delivery
10.3390/vaccines12101148 · 2024 · External reference
Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics
10.1038/s12276-023-01086-x · 2023 · External reference
Contribution of Kupffer cells to liposome accumulation in the liver
10.1016/j.colsurfb.2017.07.014 · 2017 · External reference
Nanoparticle-liver interactions: Cellular uptake and hepatobiliary elimination
10.1016/j.jconrel.2016.01.020 · 2016 · External reference
Lessons from the first-in-human in vivo CRISPR/Cas9 editing of the TTR gene by NTLA-2001 trial in patients with transthyretin amyloidosis with cardiomyopathy
10.21542/gcsp.2023.4 · 2023 · External reference
Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates
10.1073/pnas.1322937111 · 2014 · External reference
Helper lipid-enhanced mrna delivery for treating metabolic dysfunction-associated fatty liver disease
10.1021/acs.nanolett.4c01458 · 2024 · External reference
Lipid-based nanoparticle technologies for liver targeting
10.1016/j.addr.2020.06.017 · 2020 · External reference
Relationship between the physicochemical properties of lipid nanoparticles and the quality of siRNA delivery to liver cells
10.1038/mt.2015.222 · 2016 · External reference
Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis
10.1038/s41467-022-35637-z · 2023 · External reference
Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver
10.1126/sciadv.abf4398 · 2021 · External reference
Nanoparticles containing oxidized cholesterol deliver mRNA to the liver microenvironment at clinically relevant doses
10.1002/adma.201807748 · 2019 · External reference
Low-liver-accumulation lipid nanoparticles enhance the efficacy and safety of HPV therapeutic tumor vaccines
10.1186/s12967-025-06924-2 · 2025 · External reference
Molecular mechanism of nanomaterials induced liver injury: A review
10.4254/wjh.v16.i4.566 · 2024 · External reference
Liver injury and cytopenia after BNT162b2 COVID-19 vaccination in an adolescent
10.1111/ped.15178 · 2022 · External reference
Understanding biophysicochemical interactions at the nano-bio interface
10.1038/nmat2442 · 2009 · External reference
Physicochemical properties determine nanomaterial cellular uptake, transport, and fate
10.1021/ar300031y · 2013 · External reference
Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of Angptl3
10.1073/pnas.2020401118 · 2021 · External reference
Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis
10.1073/pnas.2116271119 · 2022 · External reference
An optimized ionizable cationic lipid for brain tumor-targeted siRNA delivery and glioblastoma immunotherapy
10.1016/j.biomaterials.2022.121645 · 2022 · External reference
Blood-brain-barrier-crossing lipid nanoparticles for mRNA delivery to the central nervous system
10.1038/s41563-024-02114-5 · 2025 · External reference
Imidazole-based synthetic lipidoids for in vivo mRNA delivery into primary T lymphocytes
10.1002/anie.202008082 · 2020 · External reference
Pancreatic-targeted lipid nanoparticles based on organ capsule filtration
10.1038/s41586-026-10158-7 · 2026 · External reference
Thiophene-based lipids for mRNA delivery to pulmonary and retinal tissues
10.1073/pnas.2307813120 · 2024 · External reference
Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8+ T cell response
10.1073/pnas.2207841119 · 2022 · External reference
On the formation and morphology of lipid nanoparticles containing ionizable cationic lipids and siRNA
10.1021/acsnano.8b01516 · 2018 · External reference
Lipid nanoparticles containing siRNA synthesized by microfluidic mixing exhibit an electron-dense nanostructured core
10.1021/jp303267y · 2012 · External reference
The role of helper lipids in optimising nanoparticle formulations of self-amplifying RNA
10.1016/j.jconrel.2024.08.016 · 2024 · External reference
Bone-marrow-homing lipid nanoparticles for genome editing in diseased and malignant haematopoietic stem cells
10.1038/s41565-024-01680-8 · 2024 · External reference
Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-cas gene editing
10.1038/s41565-020-0669-6 · 2020 · External reference
On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles
10.1073/pnas.2109256118 · 2021 · External reference
Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation
10.1038/s41467-024-50093-7 · 2024 · External reference
One-component cationic lipids for systemic mRNA delivery to splenic T cells
10.1002/ange.202405444 · 2024 · External reference
Hydrogen bond-assisted two-component lipid nanoparticles for spleen-specific mRNA delivery
10.1021/jacs.5c14194 · 2025 · External reference
Applications of surface modification technologies in nanomedicine for deep tumor penetration
10.1002/advs.202002589 · 2021 · External reference
Surface modification and endothelialization of biomaterials as potential scaffolds for vascular tissue engineering applications
10.1039/c4cs00483c · 2015 · External reference
Surface functionalization of exosomes for target-specific delivery and in vivo imaging & tracking: Strategies and significance
10.1016/j.jconrel.2020.07.042 · 2020 · External reference
10.1038/s41596-025-01330-w
10.1038/s41596-025-01330-w · External reference
In vivo hematopoietic stem cell modification by mRNA delivery
10.1126/science.ade6967 · 2023 · External reference
Targeted delivery of lipid nanoparticle to lymphatic endothelial cells via anti-podoplanin antibody
10.1016/j.jconrel.2022.06.052 · 2022 · External reference
EGFR-targeted ionizable lipid nanoparticles enhance in vivo mRNA delivery to the placenta
10.1016/j.jconrel.2024.05.036 · 2024 · External reference
CAR T cells produced in vivo to treat cardiac injury
10.1126/science.abm0594 · 2022 · External reference
Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo
10.1016/j.jconrel.2022.08.033 · 2022 · External reference
In vivo CAR T cell generation to treat cancer and autoimmune disease
10.1126/science.ads8473 · 2025 · External reference
A versatile antibody capture system drives specific in vivo delivery of mRNA-loaded lipid nanoparticles
10.1038/s41565-025-01954-9 · 2025 · External reference
Conformation-sensitive targeting of lipid nanoparticles for RNA therapeutics
10.1038/s41565-021-00928-x · 2021 · External reference
A modular platform for targeted RNAi therapeutics
10.1038/s41565-017-0043-5 · 2018 · External reference
Peptide-drug conjugates (PDCs): A novel trend of research and development on targeted therapy, hype or hope
10.1016/j.apsb.2022.07.020 · 2023 · External reference
CD47 peptide-cloaked lipid nanoparticles promote cell-specific mRNA delivery
10.1016/j.ymthe.2025.03.018 · 2025 · External reference
In vivo mRNA delivery to virus-specific T cells by light-induced ligand exchange of MHC class I antigen-presenting nanoparticles
10.1126/sciadv.abm7950 · 2022 · External reference
Peptide-guided lipid nanoparticles deliver mRNA to the neural retina of rodents and nonhuman primates
10.1126/sciadv.add4623 · 2023 · External reference
Tissue-specific mRNA delivery and prime editing with peptide-ionizable lipid nanoparticles
10.1038/s41563-025-02320-9 · 2026 · External reference
Cetirizine: Actions on neurotransmitter receptors
10.1016/s0091-6749(05)80248-9 · 1990 · External reference
Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection
10.1126/sciadv.abb4429 · 2020 · External reference
Oligonucleotide aptamers: New tools for targeted cancer therapy
10.1038/mtna.2014.32 · 2014 · External reference
Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy
10.1038/nm.3791 · 2015 · External reference
Rational design of bisphosphonate lipid-like materials for mRNA delivery to the bone microenvironment
10.1021/jacs.2c02706 · 2022 · External reference
Lymphatic targeting by albumin-hitchhiking: Applications and optimisation
10.1016/j.jconrel.2020.07.046 · 2020 · External reference
Evans blue dye: A revisit of its applications in biomedicine
10.1155/2018/7628037 · 2018 · External reference
Albumin-recruiting lipid nanoparticle potentiates the safety and efficacy of mRNA vaccines by avoiding liver accumulation
10.1038/s41563-025-02284-w · 2025 · External reference
Nucleoside-modified VEGFC mRNA induces organ-specific lymphatic growth and reverses experimental lymphedema
10.1038/s41467-021-23546-6 · 2021 · External reference
Ionizable lipid nanoparticles for in vivo mRNA delivery to the placenta during pregnancy
10.1021/jacs.2c12893 · 2023 · External reference
Ionizable lipid nanoparticles for in utero mRNA delivery
10.1126/sciadv.aba1028 · 2021 · External reference
Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines
10.1038/s41565-023-01404-4 · 2023 · External reference
Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines
10.1016/j.omtn.2019.01.013 · 2019 · External reference
Enhancing the immunogenicity of lipid-nanoparticle mRNA vaccines by adjuvanting the ionizable lipid and the mRNA
10.1038/s41551-023-01082-6 · 2025 · External reference
Screening for lipid nanoparticles that modulate the immune activity of helper T cells towards enhanced antitumour activity
10.1038/s41551-023-01131-0 · 2024 · External reference
Efficient delivery of VEGFA mRNA for promoting wound healing via ionizable lipid nanoparticles
10.1016/j.bmc.2022.117135 · 2023 · External reference
Close the cancer-immunity cycle by integrating lipid nanoparticle-mRNA formulations and dendritic cell therapy
10.1038/s41565-023-01453-9 · 2023 · External reference
Cryo-shocked cancer cells for targeted drug delivery and vaccination
10.1126/sciadv.abc3013 · 2020 · External reference
Inhaled drug delivery: Past, present, and future
10.1016/j.nantod.2023.101942 · 2023 · External reference
Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation
10.1126/sciadv.1601556 · 2017 · External reference
Combinatorial design of nanoparticles for pulmonary mRNA delivery and genome editing
10.1038/s41587-023-01679-x · 2023 · External reference
Optimized inhaled LNP formulation for enhanced treatment of idiopathic pulmonary fibrosis via mRNA-mediated antibody therapy
10.1038/s41467-024-51056-8 · 2024 · External reference
Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs
10.1038/s41551-021-00786-x · 2021 · External reference
Ionizable lipid nanoparticles deliver mRNA to pancreatic β cells via macrophage-mediated gene transfer
10.1126/sciadv.ade1444 · 2023 · External reference
Ionizable guanidine-based lipid nanoparticle for targeted mRNA delivery and cancer immunotherapy
10.1126/sciadv.adx5970 · 2025 · External reference
Non-viral delivery of chemically modified mRNA to the retina: Subretinal versus intravitreal administration
10.1016/j.jconrel.2019.06.042 · 2019 · External reference
Lipid nanoparticles for delivery of messenger RNA to the back of the eye
10.1016/j.jconrel.2019.04.015 · 2019 · External reference
Lipid nanoparticles with PEG-variant surface modifications mediate genome editing in the mouse retina
10.1038/s41467-023-42189-3 · 2023 · External reference
The skin you are in: Design-of-experiments optimization of lipid nanoparticle self-amplifying RNA formulations in human skin explants
10.1021/acsnano.9b01774 · 2019 · External reference
Lipid nanoparticle-mediated hit-and-run approaches yield efficient and safe in situ gene editing in human skin
10.1021/acsnano.3c08644 · 2023 · External reference
A microneedle vaccine printer for thermostable COVID-19 mRNA vaccines
10.1038/s41587-023-01774-z · 2024 · External reference
In vivo introduction of mRNA encapsulated in lipid nanoparticles to brain neuronal cells and astrocytes via intracerebroventricular administration
10.1021/acs.molpharmaceut.7b01084 · 2018 · External reference
Ionizable lipid nanoparticles for therapeutic base editing of congenital brain disease
10.1021/acsnano.3c02268 · 2023 · External reference
Lipid nanoparticles deliver mRNA to the brain after an intracerebral injection
10.1021/acs.biochem.3c00371 · 2023 · External reference
LNPs-mediated VEGF-C mRNA delivery promotes heart repair and attenuates inflammation by stimulating lymphangiogenesis post-myocardial infarction
10.1016/j.biomaterials.2025.123410 · 2025 · External reference
10.1038/s41551-025-01523-4
10.1038/s41551-025-01523-4 · External reference
Lipid nanoparticles-encapsulated brain-derived neurotrophic factor mRNA delivered through the round window niche in the cochleae of guinea pigs
10.1007/s00221-020-05970-0 · 2021 · External reference
Scaffold-mediated CRISPR-Cas9 delivery system for acute myeloid leukemia therapy
10.1126/sciadv.abg3217 · 2021 · External reference
Optimization of lipid nanoparticles for gene editing of the liver via intraduodenal delivery
10.1016/j.biomaterials.2024.122559 · 2024 · External reference
Synthetic and biogenic materials for oral delivery of biologics: From bench to bedside
10.1021/acs.chemrev.4c00482 · 2025 · External reference
Size-controlled lipid nanoparticle production using turbulent mixing to enhance oral DNA delivery
10.1016/j.actbio.2018.09.047 · 2018 · External reference
Oral mRNA delivery using capsule-mediated gastrointestinal tissue injections
10.1016/j.matt.2021.12.022 · 2022 · External reference
An ingestible self-orienting system for oral delivery of macromolecules
10.1126/science.aau2277 · 2019 · External reference
A nanoparticle platform for accelerated in vivo oral delivery screening of nucleic acids
10.1002/adtp.202000111 · 2021 · External reference
Oral delivery of IL-22 mRNA-loaded lipid nanoparticles targeting the injured intestinal mucosa: A novel therapeutic solution to treat ulcerative colitis
10.1016/j.biomaterials.2022.121707 · 2022 · External reference
Host genetic factors determining COVID-19 susceptibility and severity
10.1016/j.ebiom.2021.103629 · 2021 · External reference
10.1007/s40265-021-01480-7
10.1007/s40265-021-01480-7 · External reference
Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase
10.1056/nejmoa2113017 · 2021 · External reference
Abstract 3252: Anti-tumor effect of the combination of a lipid nanoparticle suspension of an AKT-1 antisense oligonucleotide (WGI-0301) with tyrosine kinase inhibitors in an orthotopic murine tumor model
10.1158/1538-7445.am2024-3252 · 2024 · External reference
Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial
10.1200/jco.2023.41.17_suppl.lba9503 · 2023 · External reference
539 Phase 1 study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L/IL-23/IL-36γ, for intratumoral (ITu) injection+/-durvalumab in advanced solid tumors and lymphoma
10.1136/jitc-2021-sitc2021.539 · 2021 · External reference
A phase 1/2 open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of OTX-2002 as a single agent and in combination with standard of care in patients with hepatocellular carcinoma and other solid tumor types known for association with the MYC oncogene (MYCHELANGELO I)
10.1200/jco.2023.41.4_suppl.tps627 · 2023 · External reference
First-in-human mRNA CAR therapy: Correlative biomarker analysis from the MT-302 phase 1 study targeting TROP2 in patients with advanced epithelial tumors
10.1200/jco.2025.43.16_suppl.2591 · 2025 · External reference
Gene therapy for glycogen storage diseases
10.1093/hmg/ddz133 · 2019 · External reference
Clinical development of therapeutic mRNA applications
10.1016/j.ymthe.2025.03.034 · 2025 · External reference
Restoring ornithine transcarbamylase (OTC) activity in an OTC-deficient mouse model using LUNAR-OTC mRNA
10.1002/ctd2.33 · 2022 · External reference
WS10.03 inhaled LUNAR®-CFTR mRNA (ARCT-032) is safe and well-tolerated: A phase 1 study
10.1016/s1569-1993(24)00166-8 · 2024 · External reference
Lung-specific mRNA delivery by ionizable lipids with defined structure-function relationship and unique protein corona feature
10.1002/advs.202416525 · 2025 · External reference
Polymer-lipid nanoparticles for systemic delivery of mRNA to the lungs
10.1002/ange.201608450 · 2016 · External reference
High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing
10.1073/pnas.1811276115 · 2018 · External reference
Piperazine-derived lipid nanoparticles deliver mRNA to immune cells in vivo
10.1038/s41467-022-32281-5 · 2022 · External reference
High-throughput barcoding of nanoparticles identifies cationic, degradable lipid-like materials for mRNA delivery to the lungs in female preclinical models
10.1038/s41467-024-45422-9 · 2024 · External reference
Enhanced immunocompatibility of ligand-targeted liposomes by attenuating natural IgM absorption
10.1038/s41467-018-05384-1 · 2018 · External reference
Quantification of available ligand density on the surface of targeted liposomal nanomedicines at the single-particle level
10.1021/acsnano.2c02084 · 2022 · External reference
Optimizing lipid nanoparticles for delivery in primates
10.1002/adma.202211420 · 2023 · External reference
Species-dependent in vivo mRNA delivery and cellular responses to nanoparticles
10.1038/s41565-021-01030-y · 2022 · External reference
Human organs-on-chips for disease modelling, drug development and personalized medicine
10.1038/s41576-022-00466-9 · 2022 · External reference
Advanced in vitro models of vascular biology: Human induced pluripotent stem cells and organ-on-chip technology
10.1016/j.addr.2018.06.007 · 2019 · External reference
Artificial intelligence-guided design of lipid nanoparticles for pulmonary gene therapy
10.1038/s41587-024-02490-y · 2025 · External reference
Artificial intelligence-driven rational design of ionizable lipids for mRNA delivery
10.1038/s41467-024-55072-6 · 2024 · External reference
10.1038/s41551-026-01640-8
10.1038/s41551-026-01640-8 · External reference
